 turn point next-gen kinas inhibit initi
coverag buy rate pt
messag initi coverag buy rate pt compani focus next-gener select
tyrosin kinas inhibitor tki inhibit driver mutat cancer take advantag uniqu medicin chemistri platform
focus macrocycl tki lead product candid repotrectinib tki enter pivot clinic develop treatment
genetically-select patient ntrk mutat updat phase data guid interim result
registr phase ii cohort read earlier-stag pipelin program anti-met
anti-ret enter clinic develop could repres upsid current valuat
rate buy pt clinical-stag biotech compani bn market cap focus
develop commerci repotrectinib select potent tki activ ntrk rearrang
 drug resist mutat repotrectinib demonstr earli potent activ non-smal cell lung cancer nsclc
patient posit may best-in-class inhibitor solid tumor patient ntrk mutat potenti
key differenti vs select tki space repotrectinib also potenti address high unmet need cancer
diseas progress prior select tki therapi includ emerg solvent front mutat larg resist
current standard care early-stag inhibitor ret inhibitor could repres upsid
current valuat pt consist repotrectinib pos-adjust estim cash year
bull-cas scenario model suggest hypothet per share valuat assum favor repotrectinib readout
think stock could hypothet trade bear-cas scenario year on-going trial
result disappoint valu attribut toward earli pipelin
market select tki target rare driver mutat oncolog repres rel new larg grow
product opportun highlight sector initi last year link expect precis medicin within oncolog continu
thrive driven variou factor includ rapid develop timelin emerg potent and/or select tki
valid commerci market emerg new genom inform driver resist mutat select
tki ntrk alon could potenti repres bn market includ braf kra fgfr etc
partial driven emerg newer potent tki also address mechan resist prior-gener tki follow
initi approv select inhibitor xalkori alk non-smal cell lung cancer nsclc global market
select inhibitor grew compound-annual-growth-rate includ select ntrk inhibitor bayri vitrakvi
 along drug street consensu estim indic compound-annual-growth-rate result bn
global market select ntrk inhibitor surprisingli compani develop tki
target recent larger biopharmaceut compani creat signific sharehold valu
page analyst certif import disclosur
repotrectinib potenti best-in-class profil ntrk two valid tki target base analysi
think advantag nsclc potenti competitor particularli patient previously-tr
select tki phase dose escal data indic impress orr tki-naiv nsclc patient blind
independ central review bicr numer higher xalkori orr entrectinib orr report
similar patient popul within tki-pretr nsclc patient repotrectinib read orr bicr
mg dose across dose includ difficult-to-treat solvent front mutat popul result
impress given lorbrena tki initi approv read orr tki-pretr
patient respons among solvent front mutat
emerg treatment landscap ntrk tumor somewhat competit though repotrectinib could emerg
compel profil bayri next-gen inhibitor macrocycl molecul similar repotrectinib design overcom
treatment resist first-gener ntrk inhibitor vitrakvi bayri demonstr activ ntrk solvent front
mutat repotrectinib yet read clinic data ntrk patient beyond patient case studi preclin data suggest
enhanc potenc compar vitrakvi well vitrakvi-resist mutant
rest pipelin potenti sourc upsid current valuat addit repotrectinib compani also disclos
preclin ind-stag asset inhibitor clear ind may enter clinic
compani believ similar potenc potenti competitor inhibitor capmatinib novn
activ potenti key differenti select ret inhibitor design inhibit wild-
type ret fusion includ confer resist multikinas inhibitor well solvent front mutat amino
acid posit may address emerg inhibitor next-gen inhibitor
undergo preclin lead identif design overcom mechan resist currently-avail tki
 compound mutation-medi resist pfe lorbrena
base-cas valuat scenario conserv forecast peak ww probability-adjust repotrectinib sale
po tki-nav po pretreat patient attribut tki-naiv patient
patient progress prior select tki model peak share repotrectinib tki-naiv
patient given competit inhibitor xalkori approv entrectinib pdufa date
tki-pretr set model rapid ramp-up peak market share given patient alreadi identifi
posit repotrectinib promis albeit earli clinic data set repotrectinib potenti alk ntrk
could repres upsid current estim valuat
upcom potenti stock catalyst pipelin event lead candid repotrectinib updat phase dose escal portion
similar patient number addit follow-up month interim data registr phase ii
cohort read ret inhibitor preclin data readout compar
currently-lead ret inhibitor
page analyst certif import disclosur
initi coverag turn point
page analyst certif import disclosur
page analyst certif import disclosur
rate buy earli clinical-stag biotech
compani platform focus select tki design
overcom tumor resist standard care tki treatment
mutat current differenti select tki
clinic proof-of-concept data tki-pretr nsclc
patient preclin asset ret
resist tumor respect indic could repres
long-term upsid current valuat pt
current share price consensu
landscap overal market opportun among tumor
rel posit among competit indic
ntrk alk ret tumor
clinic potenti early-stag asset
repotrectinib data updat nsclc
repotrectinib initi data ntrk tumor
repotrectinib initi data tumor
chart slide overal market perform
page analyst certif import disclosur
clinical-stag biotech compani develop specif tyrosin kinas inhibitor treatment-resist cancer pipelin
focus smaller compact tki potenti overcom cancer resist includ solvent front mutat remain unaddress
standard care tki
lead clinic candid repotrectinib could potenti address solvent front mutat alk ntrk confer resist
current approv tki xalkori unaddress recent tki includ vitrakvi entrectinib
pipelin asset includ inhibitor enter phase clinic trial well preclin asset
ret/src inhibitor inhibitor
page analyst certif import disclosur
unmet need treatment-resist cancer
success repotrectinib could first- best-in-class
tki nsclc solvent front mutat
potenti superior tki solvent mutat
front activ base preclin data
treatment-resist tumor high unmet need
bear clinic data still earli compani
highli competit field
repotrectinib data-to-d tki-pretr
nsclc still earli patient
potenti competit inhibitor solvent front
mutat activ ntrk previous
announc gen ret loxo acquisit
overal opportun unknown within ret alk tumor
solvent front mutat
pipelin beyond repotrectinib yet enter clinic
current single-product stori could address high
unmet need genetically-defin patient repotrectinib
next-gener inhibitor
specif design address treatment resist
currently-avail therapi preclin earli clinic data
inhibitor ntrk
readout may serv potenti stock
catalyst updat phase data expect
addit follow-up durabl compani
guid readout interim data
registr cohort includ nsclc tki-
nave pretreat patient ntrk solid tumor
tki-nav pretreat patient trial also includ
exploratori cohort tki-nav alk non-nsclc tumor
earli pipelin consist ret inhibitor could
sourc long-term upsid target
extern valid tptx program success could
address emerg resist respect indic
revenu forecast street consensu
averag pt current share
price slightli peer estim
upsid downsid bull/bear case
page analyst certif import disclosur
per dcf
 regulatori commerci setback
potenti emerg new competitor
dilut financ beyond assum
po nsclc tki-nav
po nsclc tki pretreat
valu repotrectinib indic
valu pipelin agent
posit readout po
repotrectinib
po repotrectinib ntrk
po repotrectinib patient
peak market share
valu repotrectinib tki-nav
valu indic pipelin asset
page analyst certif import disclosur
compani platform focus small macrocycl tki overcom
resist mutat steric hinder drug bind
major approv ntrk inhibitor tend larger mw acycl molecul
potenti best-in-class platform make smaller macrocycl tki overcom resist
founder cso
jingrong jean cui
lead inventor lorlatinib
suscept solvent front mutat
guggenheim secur llc analysi imag pubchem nation institut link
page analyst certif import disclosur
tptx manag team extens scientif clinic experi
develop tki oncolog therapeut
ceo presid athena countourioti md
multipl clinic develop chief medic offic role past year includ
public record includ clinic report multipl commerci tki includ bosutinib bosulif link link link sunitinib sutent
pediatr hematologist/oncologist train md tuft univers pediatr resid ucla pediatr hematology-oncolog train
fred hutchinson cancer research center
member board director trovagen trov numedii privat compani iovanc addit
cso scientif founder jingrong jean cui phd
lead inventor select inhibitor crizotinib xalkori lorlatinib lorbrena
author multipl peer-review articl describ select tki resist mechan thereof includ
identif mutat exposur crizotinib ceritinib zykadia novn link
design addit inhibitor crizotinib-resist mutat link
discoveri character select alloster trka inhibitor link select c-met tki link link link
medicin chemist train phd organ chemistri bs/m chemistri profession experi
svp clinic develop robert xin md phd
multipl clinic develop medic affair role past year includ rhhbi
experi includ multipl drug approv vemurafenib zelboraf rhhbi obinutuzumab gazyva rhhbi vismodegib erivedg
rhhbi rituximab rituxan rhhbi sunitinib sutent
physician-scientist train md ms pharmacolog zhejiang univers phd cell molecular physiolog unc chapel hill
page analyst certif import disclosur
trk inhibitor could repres market
histor sale street consensu select ntrk inhibitor
dsnky/anheart ensartinib xcoveri belizatinib
amgn/gsk includ within consensu estim
page analyst certif import disclosur
histor use select inhibitor led emerg resist
mutant follow newer potent tki overcom resist
fda approv timelin select trk inhibitor
mutat
post-zykadia
page analyst certif import disclosur
select small molecul tumor inhibitor target recent
 larger biopharmaceut compani
list recent acquir innov biotech select inhibitor
price premium defin premium stock price day deal announc vs stock price day prior announc
close acquisit bayri exercis option full develop commerci right trk inhibitor profil
ret inhibitor program discontinu acquisit
page analyst certif import disclosur
on-going pivot trial potenti establish
repotrectinib statu best-in-class inhibitor ntrk
advanc metastat solid tumor
ntrk rearrang
prior chemo immunotherapi allow
confirm orr bicr
page analyst certif import disclosur
compani highlight takeaway fda end phase meet
includ benchmark acceler repotrectinib approv
base statist analysi management comment believ acceler approv benchmark nsclc
cohort could orr tki-nav pre-treat patient respect
acceler approv lower bound ci repotrectinib orr exce benchmark therapi report orr accord management
tki-nav cohort benchmark xalkori orr calcul orr requir lower ci bound clopper-pearson
tki-pretr cohort benchmark cyramza orr calcul orr requir lower ci bound
 calcul orr bicr prior tki patient dose lower ci bound current
 calcul orr bicr prior tki patient dose lower ci bound current
lower bound ci vari orr patient
lower bound ci vari orr patient
accel approv
benchmark
approv
year f/u
accel approv
benchmark
approv
year f/u
confirm orr bicr
confirm orr bicr
repotrectinib orr similar benchmark fda allow full approv addit one year
follow-up greater line sight durabl similar entrectinib accord comment
loos guidanc ntrk cohort beyond need tumor type year follow-up data
posit earli feedback trial site investig clinician place initi ntrk patient onto consid commercially-
may submit registr data cohort matur rather wait trial complet
compani believ cohort nsclc patient prior tki exposur like matur interim readout
page analyst certif import disclosur
pre- post-crizotinib biopsi studi suggest half progressor
addl mutat potenti address repotrectinib
mechan resist post-crizotinib patient
differenti clinic profil
potenti mechan resist
bypass inhibit studi assay
mechan includ ra mutat
activ wild-typ egfr
potenti mechan resist
gainor solvent-
front mutat identifi mediat crizotinib-resist
mccoach concurr gatekeep
solvent-front mutat oncogen mutat
page analyst certif import disclosur
